A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica
Phase of Trial: Phase III
Latest Information Update: 10 Feb 2019
At a glance
- Drugs Sarilumab (Primary) ; Prednisone
- Indications Polymyalgia rheumatica
- Focus Therapeutic Use
- Sponsors Sanofi
- 24 Sep 2018 Status changed from not yet recruiting to recruiting.
- 01 Aug 2018 New source identified and integrated (ClinicalTrials.gov: NCT03600818).
- 17 Jul 2018 Status changed from planning to not yet recruiting.